Impact of varicella vaccine on varicella-zoster virus dynamics

Clinical Microbiology Reviews

Volumn 23, Issue 1, 2010, Pages 202-217

  Schmid, D Scott ^a   Jumaan, Aisha O ^a,b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b PATH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; STEROID;

CHICKENPOX; DRUG EFFICACY; DYNAMICS; GENETICS; HERPES ZOSTER; HUMAN; IMMUNITY; LABORATORY TEST; MOLECULAR EVOLUTION; MORBIDITY; PATHOGENICITY; PROTECTION; RECIPIENT; REVIEW; RISK FACTOR; TREATMENT FAILURE; UNITED STATES; VARICELLA ZOSTER VIRUS;

CHICKENPOX; CHICKENPOX VACCINE; CLINICAL LABORATORY TECHNIQUES; DISEASE OUTBREAKS; HERPESVIRUS 3, HUMAN; HUMANS; UNITED STATES;

HUMAN HERPESVIRUS 3;

EID: 74249123005     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00031-09     Document Type: Review

References (159)

1. Ampofo, K., L. Saiman, P. LaRussa, S. Steinberg, P. Annunziato, and A. Gershon. 2002. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin. Infect. Dis. 34:774-779.
2. Arbeter, A. M., S. E. Starr, and S. A. Plotkin. 1986. Varicella vaccine studies in healthy children and adults. Pediatrics 78:748-756.
3. Arvin, A. M. 1996. Immune responses to varicella-zoster virus. W. B. Saunders, Philadelphia, PA.
4. Asano, Y., T. Nagai, T. Miyata, T. Yazaki, S. Ito, K. Yamanishi, and M. Takahashi. 1985. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 75:667-671.
5. Asano, Y., S. Suga, T. Yoshikawa, I. Kobayashi, T. Yazaki, M. Shibata, K. Tsuzuki, and S. Ito. 1994. Experience and reason: twenty year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94:524-526.
6. Baba, K., K. Shiraki, T. Kanesaki, K. Yamanishi, P. L. Ogra, H. Yabuuchi, and M. Takahashi. 1987. Specificity of skin test with varicella-zoster virus antigen in varicella-zoster and herpes simplex virus infections. J. Clin. Microbiol. 25:2193-2196.
7. Barrett-Muir, W., F. T. Scott, P. Aaby, J. John, P. Matondo, Q. L. Chaudry, M. Siquera, A. Poulsen, K. Yamanishi, and J. Breuer. 2003. Genetic variation of varicella-zoster virus: evidence for geographical separation of strains. J. Med. Virol. 70(Suppl.):S42-S47.
8. Bernstein, H. H., E. P. Rothstein, Pennridge Pediatric Associates, B. M. Watson, K. S. Reisinger, M. M. Blatter, C. O. Wellman, S. A. Chartrand, I. Cho, A. Ngail, and C. J. White. 1993. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 92:833-837.
9. Black, S., P. Ray, H. Shinefield, P. Saddler, and A. Nikas. 2008. Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. J. Infect. Dis. 197(Suppl. 2):S139-S142.
10. Breuer, J., and D. S. Schmid. 2008. Vaccine Oka variants and sequence variability in vaccine-related skin lesions. J. Infect. Dis. 197(Suppl. 2):S54-S57.
11. Breuer, J., D. S. Schmid, and A. A. Gershon. 2008. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough in vaccinees and to screen for susceptibles. J. Infect. Dis. 197(Suppl. 2):S147-S151.
12. Brisson, M., N. J. Gay, W. J. Edmunds, and N. J. Andrews. 2002. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20:2500-2507.
13. Brisson, M., W. J. Edmunds, N. J. Gay, B. Law, and G. De Serres. 2000. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol. Infect. 125:651-669.
14. Broyer, M., and M. J. Tete. 1997. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 99:35-39.
15. Brunell, P. A., J. Taylor-Wiedeman, C. F. Geiser, L. Frierson, and E. Lydick. 1986. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 77:53-56.
16. Buchholz, U., R. Moolenaar, C. Peterson, and L. Mascola. 1999. Varicella outbreaks after vaccine licensure: should they make you chicken? Pediatrics 104:561-563.
17. Campsall, S. A., N. H. C. Au, J. S. Prendiville, D. P. Speert, R. Tan, and E. E. Thomas. 2004. Detection and genotyping of varicella-zoster virus by TaqMan allelic discrimination real-time PCR. J. Clin. Microbiol. 42:1409-1413.
18. CDC. 2003. Decline in annual incidence of varicella - selected states, 1990-2001. MMWR Morb. Mortal. Wkly. Rep. 52:884-885.
19. CDC. 1997. Immunization of health care workers: recommendations of Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb. Mortal. Wkly. Rep. 46:1-42.
20. CDC. 2006. National, state, and urban area vaccination coverage among children aged 19-35 months - United States, 2005. MMWR Morb. Mortal. Wkly. Rep. 55:988-993.
21. CDC. 2004. Outbreak of varicella among vaccinated children - Michigan, 2003. MMWR Morb. Mortal. Wkly. Rep. 53:389-392.
22. CDC. 1996. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 45(RR11):1-36.
23. CDC. 1999. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 48(RR6):1-5.
24. CDC. 2009. Immunization coverage in the United States - National Immunization Survey (NIS). Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/vaccines/stats-surv/imz-coverage.htm#nis.
25. Chaves, S. S., J. Zhang, R. Civen, B. M. Watson, T. Carbajal, D. Perella, and J. F. Seward. 2008. Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005. J. Infect. Dis. 197:S127-S131.
26. Chen, J. J., Z. Zhu, A. A. Gershon, and M. D. Gershon. 2004. Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell 119:915-926.
27. Reference deleted.
28. Civen, R., S. S. Chaves, A. Jumaan, H. Wu, L. Mascola, P. Gargiullo, and J. F. Seward. 2009. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr. Infect. Dis. J. 28:954-959.
29. Clements, D. A., S. P. Moreira, P. M. Coplan, C. L. Bland, and E. B. Walter. 1999. Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr. Infect. Dis. J. 18:1047-1050.
30. Coffin, S. E., and R. L. Hodinka. 1995. Utility of direct immunofluorescence and virus culture for detection of varicella-zoster virus in skin lesions. J. Clin. Microbiol. 33:2792-2795.
31. Cohen, P. R. 1994. Tests for detecting herpes simplex virus and varicella-zoster virus. Dermatol. Clin. 12:51-68.
32. Davis, M. M., M. S. Patel, and A. Gebremariam. 2004. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 114:786-792.
33. Davison, A. J., and J. E. Scott. 1986. The complete DNA sequence of varicella-zoster virus. J. Gen. Virol. 67:1759-1816.
34. Donahue, J. G., P. W. Choo, J. E. Manson, and R. Platt. 1995. The incidence of herpes zoster. Arch. Intern. Med. 155:1605-1609.
35. Dworkin, M. S., C. E. Jennings, J. Roth-Thomas, J. E. Lang, C. Stukenberg, and J. R. Lumpkin. 2002. An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin. Infect. Dis. 35:102-104.
36. Engelman, I., D. R. Petzold, A. Kosinska, B. G. Hepkema, T. F. Schulz, and A. Heim. 2008. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J. Med. Virol. 80:467-477.
37. Espy, M. J., R. Teo, T. K. Ross, K. A. Suien, A. D. Wold, J. R. Uhl, and T. F. Smith. 2000. Diagnosis of varicella-zoster virus infections in the clinical laboratory by LightCycler PCR. J. Clin. Microbiol. 38:3187-3189.
38. Fine, P. E., and E. R. Zell. 1994. Outbreaks in highly vaccinated populations: implications for studies of vaccine performance. Am. J. Epidemiol. 139:77-90.
39. Fleming, D. M., K. W. Cross, W. A. Cobb, and R. S. Chapman. 2004. Gender difference in the incidence of shingles. Epidemiol. Infect. 132:1-5.
40. Folkers, E., J. Vreeswijk, A. P. Oranje, F. Waganaar, and J. N. Duivenvoorden. 1991. Improved detection of HSV by electron microscopy: comparison with viral culture and cytodiagnosis. J. Virol. Methods 34:273-289.
41. Galil, K., C. Brown, F. Lin, and J. Seward. 2002. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr. Infect. Dis. J. 21:931-935.
42. Galil, K., E. Fair, N. Mountcastle, P. Britz, and J. Seward. 2002. Younger age at vaccination may increase risk of varicella vaccine failure. J. Infect. Dis. 186:102-105.
43. Galil, K., B. Lee, T. Strine, C. Carraher, A. L. Baughman, M. Eaton, J. Montero, and J. Seward. 2002. Outbreak of varicella at a day-care center despite vaccination. N. Engl. J. Med. 347:1909-1915.
44. Gershon, A., J. Chen, P. LaRussa, and S. Steinberg. 2007. Varicella-zoster virus: virology, p. 1537-1548. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
45. Gershon, A. A., P. S. LaRussa, and S. P. Steinberg. 1994. Detection of antibodies to varicella zoster virus using a latex agglutination assay. Clin. Diagn. Virol. 2:271-277.
46. Gershon, A. A., P. LaRussa, S. Steinberg, N. Mervish, S. H. Lo, and P. Meier. 1996. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J. Infect. Dis. 173:450-453.
47. Gershon, A. A., S. Piomelli, M. Karpatkin, E. Smithwick, and S. Steinberg. 1978. Antibody to varicella-zoster virus after passive immunization against chickenpox. J. Clin. Microbiol. 8:733-735.
48. Gershon, A. A., S. Steinberg, and the NIAID Collaborative Varicella Vaccine Study Group. 1990. Live attenuated varicella vaccine: protection in healthy adults in comparison to leukemic children. J. Infect. Dis. 161:661-666.
49. Gidding, H. F., M. Brisson, C. R. Macintyre, and M. A. Burgess. 2005. Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia. Aust. N. Z. J. Public Health 29:544-551.
50. Gomi, Y., H. Sunamachi, Y. Mori, K. Nagaike, M. Takahashi, and K. Yamanishi. 2002. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J. Virol. 76:11447-11459.
51. Gordon, J. E. 1962. Chickenpox: an epidemiologic review. Am. J. Med. Sci. 224:362-389.
52. Greaves, C. A., C. F. Lee, C. I. Bustamante, and J. D. Meyers. 1988. Use of murine monoclonal antibodies for laboratory diagnosis of varicella-zoster virus infection. J. Clin. Microbiol. 26:1623-1625.
53. Guess, H. A., D. D. Broughton, L. J. Melton, and L. T. Kurland. 1985. Epidemiology of herpes zoster in children and adolescents: a populationbased study. Pediatrics 76:512-517.
54. Guris, D., A. O. Jumaan, L. Mascola, B. M. Watson, J. X. Zhang, S. S. Chaves, P. Gargiullo, D. Perella, R. Civen, and S. F. Seward. 2008. Changing varicella epidemiology in active surveillance sites - United States, 1995-2005. J. Infect. Dis. 197(Suppl. 2):S71-S75.
55. Haberland, M., U. Meyer-König, and F. T. Hufert. 1999. Variation within the glycoprotein B gene of human cytomegalovirus is due to homologous recombination. J. Gen. Virol. 80:1495-1500.
56. Haddad, M. B., M. B. Hill, A. T. Pavia, C. E. Green, A. O. Jumaan, A. K. De, and R. T. Rolfs. 2005. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics 115:1488-1493.
57. Hammond, O., Y. Wang, T. Green, J. Antonello, R. Kuhn, C. Motley, P. Stump, B. Rich, N. Chirmule, and R. D. Marchese. 2006. The optimization and validation of the glycoprotein ELISA assay for quantitative varicellazoster virus (VZV) antibody detection. J. Med. Virol. 78:1679-1687.
58. Hardy, I., A. A. Gershon, S. Steinberg, and P. LaRussa. 1991. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N. Engl. J. Med. 325:1545-1550.
59. Harpaz, R., I. R. Ortega-Sanchez, J. F. Seward, and the Advisory Committee on Immunization Practices. 2008. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 57(RR5):1-30.
60. Hope-Simpson, R. E. 1965. The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Med. 58:9-20.
61. Reference deleted.
62. Insinga, R. P., R. F. Itzler, J. M. Pellissier, P. Saddier, and A. A. Nikas. 2005. The incidence of herpes zoster in a United States administrative database. J. Gen. Intern. Med. 20:748-753.
63. Izurieta, H. S., P. M. Strebel, and P. A. Blake. 1997. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 278:1495-1499.
64. Johnson, C. E., T. Stancin, D. Fattlar, L. P. Rome, and M. L. Kumar. 1997. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 100:761-766.
65. Josephson, A., and M. E. Gombert. 1988. Airborne transmission of nosocomial varicella from localized zoster. Pediatrics 158:238-241.
66. Jumaan, A. O., O. Yu, L. A. Jackson, K. Bohlke, K. Galil, and J. F. Seward. 2005. Incidence of herpes zoster, before and after varicella-vaccination associated decreases in the incidence of varicella, 1992-2002. J. Infect. Dis. 191:2002-2007.
67. Kamiya, H., T. Kato, M. Isaji, S. Torigoe, K. Oitani, M. Ito, T. Ihara, M. Sakurai, and M. Takahashi. 1984. Immunization of acute leukemic children with a live varicella vaccine (Oka strain). Biken J. 27:99-102.
68. Kilgore, P. E., D. Kruszon-Moran, J. F. Seward, A. Jumaan, F. P. L. Van Loon, B. Forghani, G. M McQuillen, M. Wharton, L. J. Fehrs, C. K. Cossen, and S. C. Hadler. 2003. Varicella in Americans from NHANES III: implications for control through routine immunization. J. Med. Virol. 70(Suppl. 1):S111-S118.
69. Kuter, B., H. Matthews, H. Shinefield, S. Black, P. Dennehy, B. Watson, K. Reisinger, L. L. Kim, L. Lupinacci, J. Hartzel, I. Chan, and the Study Group for Varivax. 2004. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr. Infect. Dis. J. 23:132-137.
70. Kuter, B. J., R. E. Weibel, H. A. Guess, H. Matthews, D. H. Morton, B. J. Neff, P. J. Provost, B. A. Watson, S. E. Starr, and S. A. Plotkin. 1991. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9:643-647.
71. LaRussa, P., O. Lungu, I. Hardy, A. Gershon, S. P. Steinberg, and S. Silverstein. 1992. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J. Virol. 66:1016-1020.
72. Lawrence, R., A. A. Gershon, R. Holzman, S. P. Steinberg, and the NIAID Varicella Vaccine Collaborative Study Group. 1988. The risk of zoster after varicella vaccination in children with leukemia. N. Engl. J. Med. 318:543-548.
73. Lee, B. R., S. L. Feaver, C. A. Miller, C. W. Hedberg, and K. R. Ehresmann. 2004. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J. Infect. Dis. 190:477-483.
74. Levin, M. J., G.-Y. Cai, M. D. Manchak, and L. I. Pizer. 2003. Varicellazoster virus DNA in cells isolated from human trigeminal ganglia. J. Virol. 77:6979-6987.
75. Li, S., A. S. F. Chan, H. Matthews, J. F. Heyse, C. Chan, B. J. Kuter, K. M. Kaplan, S. J. R. Vessey, and J. C. Sadoff. 2002. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr. Infect. Dis. J. 21:337-342.
76. Lolekha, S., W. Tanthiphabha, P. Sornchai, P. Kosuwan, S. Sutra, B. Warachit, S. Chup-Upprakarn, Y. Hutagalung, J. Weil, and H. L. Bock. 2001. Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country. Am. J. Trop. Med. Hyg. 64:131-136.
77. Loparev, V. N., T. Argaw, P. R. Krause, M. Takayama, and D. S. Schmid. 2000. Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J. Clin. Microbiol. 38:3156-3160.
78. Loparev, V. N., E. Rubtcova, V. Bostik, D. Govil, C. J. Birch, J. D. Druce, D. S. Schmid, and M. C. Croxson. 2007. Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand. J. Virol. 81:12758-12765.
79. Loparev, V. N., E. Rubtcova, J. F. Seward, M. J. Levin, and D. S. Schmid. 2007. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J. Infect. Dis. 195:502-510.
80. Loparev, V., E. Martro, E. Rubtcova, C. Rodrigo, J.-C. Piette, E. Caumes, J.-P. Vernant, D. S. Schmid, and A.-M. Fillet. 2007. Toward universal varicella-zoster virus (VZV) genotyping: diversity of VZV strains from France and Spain. J. Clin. Microbiol. 45:559-563.
81. Loparev, V. N., K. McCaustland, B. P. Holloway, P. R. Krause, M. Takayama, and D. S. Schmid. 2000. Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes. J. Clin. Microbiol. 38:4315-4319.
82. Loparev, V. N., A. Gonzalez, M. Deleon-Carnes, G. Tipples, H. Fickenscher, E. G. Torfason, and D. S. Schmid. 2004. Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping. J. Virol. 78:8349-8358.
83. Lopez, A. S., A. Burnett-Hartman, R. Nambler, L. Ritz, P. Owens, V. N. Loparev, D. Guris, and D. S. Schmid. 2008. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term care facility, West Virginia, 2004. J. Infect. Dis. 197:646-653.
84. Lopez, A. S., D. Guris, L. Zimmerman, L. Gladden, T. Moore, D. T. Haselow, V. N. Loparev, D. S. Schmid, A. O. Jumaan, and S. L. Snow. 2006. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics 117:e1070-e1077.
85. Ludwig, G., F. B. Kraus, R. Allwinn, S. Keim, H. W. Doerr, and S. Buxbaum. 2006. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination. Infection 34:222-226.
86. Lungu, O., P. W. Annunziato, A. Gershon, S. M. Staugaitis, D. Josefson, P. LaRussa, and S. J. Silverstein. 1995. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc. Natl. Acad. Sci. U. S. A. 92:10980-10984.
87. Maple, P. A., J. Gray, J. Breuer, G. Kafatos, S. Parker, and D. Brown. 2006. Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial immunoassays and Merck glycoprotein enzyme immunoassay. Clin. Vaccine Immunol. 13:214-218.
88. Maple, P. A. C., J. Gray, K. Brown, and D. Brown. 23 January 2009. Performance characteristics of a quantitative, standardized varicella IgG time-resolved fluorescence immunoassay (VZV TRFIA) for measuring antibody following natural infection. J. Virol. Methods [ePub ahead of print.] doi.10.1016/j.jviromet.2008.12.007.
89. Marin, M., D. Guris, S. S. Chaves, S. Schmid, J. F. Seward, and the Advisory Committee on Immunization Practices. 2007. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 56(RR4):1-40.
90. Marin, M., H. Q. Nguyen, J. Keen, A. O. Jumaan, P. M. Mellen, E. B. Hayes, K. F. Gensheimer, J. Gunderman-King, and J. F. Seward. 2005. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003. Pediatrics 115:900-905.
91. McGeoch, D. J., F. J. Rixon, and A. J. Davison. 2006. Topics in herpesvirus genomics and evolution. Virus Res. 117:90-104.
92. Michalik, D. E., S. P. Steinberg, P. S. LaRussa, K. M. Edwards, P. F. Wright, A. M. Arvin, H. A. Gans, and A. A. Gershon. 2008. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J. Infect. Dis. 197:944-949.
93. Midgley, R. S., N. W. Blake, Q. Y. Yao, D. Croom-Carter, S. T. Cheung, S. F. Leung, A. T. C. Chan, P. J. Johnson, D. Huang, A. B. Rickenson, and S. P. Lee. 2000. Novel intertypic recombinants of Epstein-Barr virus in the Chinese population. J. Virol. 74:1544-1548.
94. Mullooly, J. P., K. Riedlinger, C. Chun, S. Weinmann, and H. Houston. 2005. Incidence of herpes zoster, 1997-2002. Epidemiol. Infect. 133:245-253.
95. Nader, S., R. Bergen, M. Sharp, and A. M. Arvin. 1995. Age-related differences in cell-mediated immunity to varicella-zoster virus in children and adults immunized with live attenuated varicella vaccine. J. Infect. Dis. 171:13-17.
96. Nahass, G. T., B. A. Goldstein, W. Y. Zhu, U. Serfling, N. S. Penneys, and C. L. Leonardi. 1992. Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection. JAMA 268:2541-2544.
97. Ngai, A. L., B. O. Staehle, B. J. Kuter, N. M. Cyanovich, I. Cho, H. Matthews, P. Keller, A. M. Arvin, B. Watson, C. J. White, and the Varivax Study Group. 1996. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr. Infect. Dis. J. 15:49-54.
98. Nguyen, H. Q., A. O. Jumaan, and J. F. Seward. 2005. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N. Engl. J. Med. 352:450-458.
99. Norberg, P., M. J. Kasubi, L. Haarr, T. Bergström, and J. A. Liljeqvist. 2007. Divergence and recombination of clinical herpes simplex virus type 2 isolates. J. Virol. 81:13158-13167.
100. Norberg, P., J.-Å. Liljeqvist, T. Bergström, S. Sammons, D. S. Schmid, and V. N. Loparev. 2006. Complete-genome phylogenetic approach to varicella-zoster virus evolution: genetic divergence and evidence for recombination. J. Virol. 80:9569-9576.
101. Okamoto, S., T. Yoshikawa, M. Ihira, K. Suzuki, and K. Shimokawa. 2004. Rapid detection of varicella-zoster virus infection by a loop-mediated isothermal amplification method. J. Med. Virol. 74:677-682.
102. Opstelten, W., G. A. Van Essen, F. Schellevis, T. J. Verheij, and K. G. Moons. 2006. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann. Epidemiol. 16:692-695.
103. Ozcan, A., M. Senol, H. Saglam, M. Seyhaw, R. Durmaz, E. Aktas, and I. H. Ozerol. 2007. Comparison of the Tzanck test and polymerase chain reaction in the diagnosis of cutaneous herpes simplex and varicella-zoster virus infections. Int. J. Dermatol. 46:1177-1179.
104. Parker, A. A., M. A. Reynolds, J. Leung, M. Anderson, A. Rey, J. R. Ortega-Sanchez, D. S. Schmid, D. Guris, and K. F. Gensheimer. 2008. Challenges to implementing second-dose varicella vaccination during an outbreak in the absence of a routine 2-dose vaccination requirement - Maine, 2006. J. Infect. Dis. 197(Suppl. 2):S101-S107.
105. Parker, C. J., K. Morgan, and M. E. Dewey. 1997. Physical illness and disability among elderly people in England and Wales: the Medical Research Council Cognitive Function and Ageing Study. J. Epidemiol. Community Health 51:494-501.
106. Parker, S. P., M. Quinlivan, Y. Taha, and J. Breuer. 2006. Genotyping of varicella-zoster virus and the discrimination of Oka vaccine strains by Taq-Man real-time PCR. J. Clin. Microbiol. 44:3911-3914.
107. Peters, G. A., S. D. Tyler, C. Grose, A. Severini, M. J. Gray, C. Upton, and G. A. Tipples. 2006. A full-genome phylogenetic analysis of varicella-zoster virus reveals a novel origin of replication-based genotyping scheme and evidence of recombination between major circulating clades. J. Virol. 80:9850-9860.
108. Plotkin, S. A., S. E. Starr, K. Connor, and D. Morton. 1989. Zoster in normal children after varicella vaccine. J. Infect. Dis. 159:1000-1001.
109. Poole, L. J., J.-C. Zong, D. M. Ciufo, D. J. Alcendor, J. S. Cannon, R. Ambinder, J. M. Orenstein, M. S. Reitz, and G. S. Hayward. 1999. Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right-hand end. J. Virol. 73:6646-6660.
110. Provost, P. J., D. L. Krah, B. J. Kuter, D. H. Morton, T. L. Schofield, E. H. Wasmuth, C. J. White, W. J. Miller, and R. W. Ellis. 1991. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 9:111-116.
111. Quinlivan, M. L., A. A. Gershon, S. P. Steinberg, and J. Breuer. 2004. Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J. Infect. Dis. 190:793-796.
112. Ragozzino, M. W., L. J. Melton III, L. T. Kurland, C. P. Chu, and H. O. Perry. 1982. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 61:310-316.
113. Ratner, A. J. 2002. Varicella-related hospitalizations in the vaccine era. Pediatr. Infect. Dis. J. 21:927-930.
114. Ross, A. H. 1962. Modification of chickenpox in family contacts by administration of gamma globulin. N. Engl. J. Med. 267:369-376.
115. Saiman, L., P. LaRussa, S. P. Steinberg, J. Zhou, K. Baron, S. Whittier, P. Della-Latta, and A. A. Gershon. 2001. Persistence of immunity to varicellazoster virus vaccination among health care workers. Infect. Control Hosp. Epidemiol. 22:279-283.
116. Sato, H., J. Yamamura, S. Kageyama, M. Kurokawa, and K. Shiraki. 2003. Superiority of varicella skin test antigen over purified varicella-zoster virus glycoproteins in monitoring booster response to Oka varicella vaccine. Vaccine 22:15-20.
117. Sauerbrei, A., and P. Wutzler. 2007. Different genotype pattern of varicella-zoster virus obtained from patients with varicella and zoster in Germany. J. Med. Virol. 79:1025-1031.
118. Sawyer, M. H., C. J. Chamberlin, Y. N. Wu, N. Aintablian, and M. R. Wallace. 1994. Detection of varicella zoster virus DNA in air samples from hospital rooms. J. Infect. Dis. 169:91-94.
119. Schirm, J., J. J. Meulenberg, G. W. Pastoor, P. C. van Voorst Vader, and F. P. Schröder. 1989. Rapid detection of varicella-zoster virus in clinical specimens using monoclonal antibodies on shell vials and smears. J. Med. Virol. 28:1-6.
120. Schmid, D. S., V. Bostik, J. Folster, N. Jensen, P. Norberg, B. Bankamp, and K. Hummel. 2008. Evidence for recombination between Oka vaccine and wild type strains among clinical varicella-zoster virus (VZV) isolates, abstr. 803. Abstr. 33rd Int. Herpesvirus Wkshp.
121. Schmidt-Chanasit, J., S. Ölschläger, S. Günther, G. Jaeger, K. Bleymehl, S. G. Schäd, G. Heckel, R. G. Ulrich, and H. W. Doerr. 13 August 2008. Molecular analysis of varicella-zoster virus strains circulating in Tanzania demonstrates the presence of genotype M1. J. Clin. Microbiol. doi:10.1128/JCM.01057-08.
122. Seiler, H. E. 1949. A study of herpes zoster particularly in its relationship to chickenpox. J. Hyg. (Lond.) 47:253-262.
123. Sengupta, N., Y. Taha, F. T. Scott, M. E. Leedham-Green, M. Quinlivan, and J. Breuer. 2007. Varicella-zoster-virus genotypes in East London: a prospective study in patients with herpes zoster. J. Infect. Dis. 196:1014-1020.
124. Sergeev, N., E. Rubtcova, V. Chizikov, D. S. Schmid, and V. N. Loparev. 2006. New mosaic subgenotype of varicella-zoster virus in the USA: VZV detection and genotyping by oligonucleotide-microarray. J. Virol. Methods 136:8-16.
125. Seward, J. F., J. X. Zhang, T. J. Maupin, L. Mascola, and A. O. Jumaan. 2004. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA 292:704-728.
126. Sharrar, R. G., P. LaRussa, S. A. Galea, S. P. Steinberg, A. R. Sweet, R. M. Keatley, M. E. Wells, W. P. Stephenson, and A. A. Gershon. 2001. The postmarketing safety profile of varicella vaccine. Vaccine 19:916-923.
127. Shinefield, H. R., S. Black, and B. J. Kuter. 2008. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine. J. Infect. Dis. 197(Suppl. 2):S152-S155.
128. Solomon, A. R. 1986. The Tzanck smear. Viable and valuable in the diagnosis of herpes simplex, zoster and varicella. J. Dermatol. 18:218-221.
129. Stránská, R., R. Schuurman, M. de Vos, and A. M. van Loon. 2004. Routine use of a highly automated and internally controlled real-time PCR assay for the diagnosis of herpes simplex and varicella-zoster virus infections. J. Clin. Virol. 30:39-44.
130. Straus, S. E. 1994. The biology of varicella-zoster virus infection. Ann. Neurol. 35(Suppl.):S4-S8.
131. Suzuki, K., T. Yoshikawa, A. Tomitaka, K. Suzuki, K. Matsunaga, and Y. Asano. 2002. Detection of varicella-zoster virus DNA in throat swabs of patients with herpes zoster and on air purifier filters. J. Med. Virol. 66:567-570.
132. Suzuki, K., T. Yoshikawa, A. Tomitaka, K. Matsunaga, and Y. Asano. 2004. Detection of aerosolized varicella-zoster virus DNA in patients with localized herpes zoster. J. Infect. Dis. 189:1009-1012.
133. Takahashi, M., K. Baba, K. Horiuchi, H. Kamiya, and Y. Asano. 1990. A live varicella vaccine. Adv. Exp. Med. Biol. 278:49-58.
134. Takahashi, M., H. Kamiya, Y. Asano, K. Shiraki, K. Baba, T. Otsuka, T. Hirota, and K. Yamanishi. 2001. Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction. Arch. Virol. Suppl. 17:161-172.
135. Takahashi, M., T. Otsuka, Y. Okuno, Y. Asano, and T. Yazaki. 1974. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet ii:1288-1290.
136. Takahashi, M., Y. Okuno, T. Otsuka, J. Osame, and A. Takamizawa. 1975. Development of a live attenuated varicella vaccine. Biken J. 18:25-33.
137. Thomas, S. L., J. G. Wheeler, and A. J. Hall. 2002. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 360:678-682.
138. Tugwell, B. D., L. E. Lee, H. Gillette, E. M. Lorber, K. Hedberg, and P. R. Cieslak. 2004. Chickenpox outbreak in a highly vaccinated school population. Pediatrics 113:455-459.
139. Umene, K., S. Oohashi, M. Yoshida, and Y. Fukumaki. 2008. Diversity of the a sequence of herpes simplex virus type 1 developed during evolution. J. Gen. Virol. 89:841-852.
140. Vázquez, M. D., P. S. LaRussa, A. A. Gershon, L. M. Niccolai, C. E. Muehlenbein, S. P. Steinberg, and E. D. Shapiro. 2004. Effectiveness over time of varicella vaccine. JAMA 291:851-855.
141. Vázquez, M. D., P. S. LaRussa, A. A. Gershon, S. P. Steinberg, K. F. Freudigman, and E. Shapiro. 2001. The effectiveness of the varicella vaccine in clinical practice. N. Engl. J. Med. 344:955-960.
142. Verstraeten, T., A. O. Jumaan, J. P. Mullooly, J. F. Seward, H. S. Izurieta, F. DeStefano, S. B. Black, R. T. Chen, and the Vaccine Safety Datalink Research Group. 2003. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 112:e98-e103.
143. Vreeswijk, J., E. Folkers, F. Waganaar, and J. G. Kapsanberg. 1988. The use of colloidal gold immunoelectron microscopy to diagnose varicella-zoster virus (VZV) infections by rapid discrimination between VZV, HSV-1 and HSV-2. J. Virol. Methods 22:255-271.
144. Waganaar, T. R., V. T. K. Chow, C. Buranathai, P. Thawatsupha, and C. Grose. 2003. The out of Africa model of varicella-zoster virus evolution: single nucleotide polymorphisms and private alleles distinguish Asian clades from European/North American clades. Vaccine 21:1072-1081.
145. Walling, D. M., A. G. Perkins, J. Webster-Cyriaque, L. Resnick, and N. Raab-Traub. 1994. The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. J. Virol. 68:7918-7926.
146. Watson, B., C. Boardman, D. Laufer, S. Piercy, N. Tustin, D. Olaleye, A. Cnaan, and S. E. Starr. 1995. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin. Infect. Dis. 20:316-319.
147. Watson, B. M., S. A. Piercy, S. A. Plotkin, and S. E. Starr. 1993. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 91:17-22.
148. Watson, B., E. Rothstein, H. Bernstein, A. Arbeter, A. Arvin, S. Chartrand, D. Clements, M. L. Kumar, K. Reisinger, M. Blatter, et al. 1995. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J. Infect. Dis. 172:217-219.
149. Weinmann, S., C. Chun, J. P. Mullooly, K. Riedlinger, H. Houston, V. N. Loparev, D. S. Schmid, and J. F. Seward. 2008. Characteristics of break-through varicella in children. J. Infect. Dis. 197(Suppl. 2):S132-S138.
150. Wharton, M. 1996. The epidemiology of varicella-zoster virus infections. Infect. Dis. Clin. North Am. 10:571-581.
151. White, C. J. 1996. Clinical trials of varicella vaccine in healthy children. Infect. Dis. Clin. North Am. 10:595-608.
152. White, C. J., B. J. Kuter, C. S. Hildebrand, K. L. Isganitis, H. Matthews, G. B. Calandra, W. J. Miller, P. J. Provost, R. W. Ellis, and R. J. Gerety. 1991. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 87:604-610.
153. White, C. J., B. J. Kuter, A. Ngai, C. S. Hildebrand, K. L. Isganitis, C. M. Patterson, A. Capra, W. J. Miller, D. L. Krah, P. J. Provost, R. W. Ellis, and G. B. Callandra. 1992. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr. Infect. Dis. J. 11:19-23.
154. Yawn, B. P., R. A. Yawn, and E. Lydick. 1997. Community impact of childhood varicella infections. J. Pediatr. 130:759-765.
155. Yih, W. K., D. R. Brooks, S. M. Lett, A. O. Jumaan, Z. Zhang, K. M. Clements, and J. F. Seward. 2005. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 5:68.
156. Yoshikawa, T., M. Ihira, K. Suzuki, S. Suga, A. Tomitaka, H. Ueda, and Y. Asano. 2001. Rapid contamination of the environment with varicella-zoster virus DNA from a patient with herpes zoster. J. Med. Virol. 63:64-66.
157. Zerboni, L., S. Nader, K. Aoki, and A. M. Arvin. 1998. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J. Infect. Dis. 177:1701-1704.
158. Zhou, F., R. Harpaz, A. O. Jumaan, C. A. Winston, and A. Shefer. 2005. Impact of varicella vaccination on health care utilization. JAMA 294:797-802.
159. Zhou, F., I. R. Ortega-Sanchez, D. Guris, A. Shefer, T. Lieu, and J. F. Seward. 2008. An economic analysis of the universal varicella vaccination program in the United States. J. Infect. Dis. 197:S156-S164.